IPO
Aurion Biotech Presses On with IPO Plans Amid Legal Dispute with Investor Alcon
Aurion Biotech, IPO, legal dispute, Alcon, cell therapy, biotech investment
Chinese Vaccine Biotech Ab&B Files for IPO, Drawing Attention from GSK, Merck, and Pfizer
Ab&B Bio-Tech, IPO, Chinese vaccine biotech, GSK, Merck, Pfizer, biotechnology, pharmaceutical industry
Sionna and Odyssey Therapeutics Kick Off 2025 Biotech IPO Wave with SEC Filings
Sionna Therapeutics, Odyssey Therapeutics, IPO filings, biotech industry, JPM Healthcare Conference, 2025 IPO market
Acelyrin Reassesses Flagship Immunology Asset Izokibep Following Multiple Clinical Trial Setbacks
Acelyrin, Izokibep, Clinical Trial Failure, Immunology, Hidradenitis Suppurativa, Psoriatic Arthritis, Biotech IPO
2024 Biotech IPOs: Insights and Trends
Biotech IPOs, 2024 IPO trends, biopharma sector, initial public offerings, venture capital investment, healthcare innovation.
BioAge Labs Halts Phase 2 Obesity Trial Due to Liver Safety Concerns Just Two Months After IPO
BioAge Labs, Phase 2 trial, obesity, liver safety concerns, azelaprag, Eli Lilly, tirzepatide, IPO
Upstream Bio Expands IPO to $255 Million, Set to Join Nasdaq Alongside CAMP4
Upstream Bio, IPO, Nasdaq, CAMP4, Biotechnology, Inflammatory Diseases, Allergic Diseases
Ceribell Pursues $101M Nasdaq IPO for Revolutionary Seizure-Spotting Headset
Ceribell, Seizure-Spotting Headset, Nasdaq IPO, Emergency Seizure Care, Brain-Reading Technology
Septerna Embarks on IPO Journey with Promising Preclinical Data and Vision to Revolutionize GPCR Drug Discovery
Septerna, IPO, GPCR, preclinical data, drug discovery, biotechnology, PTH1R agonists, hypoparathyroidism
Zephyrm Seeks Hong Kong IPO to Fund Phase III Cell Therapy Trials
Zephyrm, IPO, cell therapy, Phase III trials, Hong Kong listing